These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 8129642

  • 1. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
    Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC.
    Arch Neurol; 1994 Mar; 51(3):292-6. PubMed ID: 8129642
    [Abstract] [Full Text] [Related]

  • 2. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
    Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC.
    Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
    [Abstract] [Full Text] [Related]

  • 3. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
    van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC.
    Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
    Bever CT, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S.
    Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
    [Abstract] [Full Text] [Related]

  • 6. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis.
    Davis FA, Stefoski D, Rush J.
    Ann Neurol; 1990 Feb; 27(2):186-92. PubMed ID: 2317014
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 10 questions about 4-aminopyridine and the treatment of multiple sclerosis.
    Bever CT.
    Neurologist; 2009 May; 15(3):161-2. PubMed ID: 19430274
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An unusual case of 4-aminopyridine toxicity in a multiple sclerosis patient: epileptic disorder or toxic encephalopathy?
    De Cauwer H, De Wolf P, Couvreur F, Mortelmans L.
    Acta Neurol Belg; 2009 Mar; 109(1):40-1. PubMed ID: 19402572
    [Abstract] [Full Text] [Related]

  • 15. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK, Sorensen PS.
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term effects of dalfampridine in patients with multiple sclerosis.
    Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG.
    J Neurol Sci; 2014 Feb 15; 337(1-2):18-24. PubMed ID: 24290498
    [Abstract] [Full Text] [Related]

  • 19. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
    Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP.
    Ann Neurol; 1990 Apr 15; 27(4):421-7. PubMed ID: 2353797
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.